Atlas Trials

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

Clinical trial NCT02900976 · COMPLETED

Trial details

NCT number
NCT02900976
Sponsor
Children's Oncology Group
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
EBV-Related Post-Transplant Lymphoproliferative DisorderMonomorphic Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative DisorderRecurrent Polymorphic Post-Transplant Lymphoproliferative DisorderRefractory Monomorphic Post-Transplant Lymphoproliferative DisorderRefractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Start date
2017-03-22
Primary completion
2021-03-31
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.